Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In the interim, NICE-approved options for weight management in adults with obesity include: Orlistat (available on NHS prescription) Semaglutide 2.4 mg (Wegovy) , recommended by NICE in 2023 for use in specific patient groups (NICE technology appraisal TA875) Tirzepatide (Mounjaro) , which received NICE approval in 2024 for obesity management (NICE technology appraisal TA1026) [18] Patients seeking advice about weight management or blood pressure control should be directed to their GP in the first instance, who can assess eligibility for currently approved treatments and refer to specialist services where appropriate
About 63.2% of participants on liraglutide achieved at least 5% body weight loss, and 33.1% achieved at least 10% loss
Elevated levels of trimethylamine oxide in muscles of deep-sea gadiform teleosts: a high-pressure adaptation
Pediatric Indications and Dosage FDA-Labeled Indications and Dosage (Pediatric) There is limited information regarding Semaglutide FDA-Labeled Indications and Dosage (Pediatric) in the drug label
US$ 26.30
US$ 26.15
US$ 23.62
US$ 25.01
US$ 29.81
US$ 20.91
